Oral or intravenous cyclophosphamide for patients with systemic lupus erythematosus?
Turner T
Record ID 32003001197
English
Authors' objectives:
This aim of this critical appraisal was to assess whether, in patients with systemic lupus erythematosus, oral cyclophosphamide is associated with more effective control of nephritis and less adverse effects than intravenous cyclophosphamide.
Authors' methods:
Critical appraisal
Details
Project Status:
Completed
URL for project:
http://www.med.monash.edu.au/healthservices/cce/evidence/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Cyclophosphamide
- Lupus Erythematosus, Systemic
- Nephritis
Contact
Organisation Name:
Centre for Clinical Effectiveness
Contact Address:
Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton, Victoria 3168, Australia. Tel: +61 3 9594 7505; Fax: +61 3 9594 7552.
Contact Name:
cce@med.monash.edu.au.
Contact Email:
cce@med.monash.edu.au.
Copyright:
Centre for Clinical Effectiveness (CCE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.